Indoco Remedies Limited has submitted to the Exchange, the financial results for the period ended March 31, 2026.
INDOCO · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 5.3 pts more than Nifty Microcap 250 and 6.4 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Indoco Remedies reported standalone revenue of Rs 42,906 lakhs for Q4 and Rs 1,63,354 lakhs for FY26, up 9.3% YoY from Rs 1,49,478 lakhs. Consolidated revenue grew to Rs 1,79,294 lakhs from Rs 1,64,129 lakhs. However, the company continues to post losses: standalone net loss of Rs 566 lakhs (vs Rs 873 lakhs loss in FY25) and consolidated net loss of Rs 9,870 lakhs (vs Rs 7,795 lakhs loss in FY25). Finance costs nearly doubled to Rs 8,850 lakhs standalone and Rs 12,225 lakhs consolidated. The auditors issued an unmodified (clean) opinion but included an Emphasis of Matter regarding FPP Holding LLC subsidiary, which has negative net worth of Rs 4,225 lakhs (standalone) and Rs 8,225 lakhs (consolidated), indicating material uncertainty about its ability to continue as a going concern. The board recommended a dividend of Rs 0.20 per share.
The company shows revenue growth but remains loss-making with worsening consolidated losses. The auditors' going concern warning for the FPP Holding subsidiary is a significant red flag. The doubling of finance costs also signals increasing financial leverage risk. Shareholders should monitor whether the company can achieve profitability and address the subsidiary's financial distress.